A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma

Investigator: Eric Bernicker, MD

Study Coordinator: Lacey Burey

Status: Enrolling

ClinicalTrials.gov Number: NCT03070392

Phone: 713.441.1159

Protocol Number: Pro00021862

Description

To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
More to Explore
Live Chat Available